| PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms (NCT05670821) | Boehringer Ingelheim | 2023-04-18 |
| Dose Reduction and Discontinuation With Anti-Fibrotic Medications (NCT05779007) | Boehringer Ingelheim | 2023-04-18 |
| Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa (NCT05819398) | Boehringer Ingelheim | 2023-04-17 |
| A Study in Healthy Men to Test How Itraconazole Influences the Amount of Zongertinib (BI 1810631) in the Blood (NCT05833139) | Boehringer Ingelheim | 2023-04-14 |
| A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906 (NCT05751226) | Boehringer Ingelheim | 2023-04-11 |
| A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver Problems (NCT05731895) | Boehringer Ingelheim | 2023-03-08 |
| A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the Blood (NCT05723874) | Boehringer Ingelheim | 2023-03-06 |
| A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer (NCT05708599) | Boehringer Ingelheim | 2023-03-01 |
| A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours) (NCT05471856) | Boehringer Ingelheim | 2023-02-24 |
| A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems (NCT05731908) | Boehringer Ingelheim | 2023-02-21 |
| A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body (NCT05707403) | Boehringer Ingelheim | 2023-02-14 |
| A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Kidney Problems (NCT05718648) | Boehringer Ingelheim | 2023-02-09 |
| INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation (NCT05151640) | Boehringer Ingelheim | 2023-02-08 |
| A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems (NCT05661344) | Boehringer Ingelheim | 2023-02-07 |
| A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Kidney Problems (NCT05718843) | Boehringer Ingelheim | 2023-02-01 |
| A Study in People With Pulmonary Fibrosis to Monitor Cough With a Wearable Device (NCT05670587) | Boehringer Ingelheim | 2023-01-16 |
| A Study to Test How Different Doses of BI 765423 Are Taken up in the Body of Healthy Men (NCT05658107) | Boehringer Ingelheim | 2023-01-16 |
| A Study in Healthy Chinese People to Test How Different Doses of BI 1015550 Are Taken up in the Body (NCT05633862) | Boehringer Ingelheim | 2023-01-13 |
| A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body (NCT05613036) | Boehringer Ingelheim | 2023-01-03 |
| Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients (NCT05503030) | Boehringer Ingelheim | 2022-12-21 |
| A Study to Test Different Imaging Techniques in Patients With Different Types of Interstitial Lung Disease (NCT05492994) | Boehringer Ingelheim | 2022-12-19 |
| Emp-Activity: Empagliflozin Functional Capacity (NCT05350202) | Boehringer Ingelheim | 2022-12-18 |
| Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder (NCT05512377) | Boehringer Ingelheim | 2022-12-13 |
| A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms (NCT05559580) | Boehringer Ingelheim | 2022-12-13 |
| Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization (NCT05395351) | Boehringer Ingelheim | 2022-11-30 |
| A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma (NCT05376800) | Boehringer Ingelheim | 2022-11-30 |
| A Study in Healthy Women to Test Whether BI 425809 Influences the Amount of a Contraceptive in the Blood (NCT05613777) | Boehringer Ingelheim | 2022-11-24 |
| A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot (NCT05536791) | Boehringer Ingelheim | 2022-11-24 |
| A Study in Healthy Men to Test Whether BI 474121 Can Reverse the Memory Problems Caused by Ketamine (NCT05451095) | Boehringer Ingelheim | 2022-11-07 |
| A Study in Healthy People to Test How BI 425809 is Taken up in the Body When Taken With or Without Food (NCT05347004) | Boehringer Ingelheim | 2022-10-25 |
| A Study in Healthy Men to Test How Esomeprazole Influences the Amount of BI 1819479 in the Blood (NCT05467475) | Boehringer Ingelheim | 2022-10-18 |
| A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) (NCT05321069) | Boehringer Ingelheim | 2022-10-06 |
| Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data (NCT05393245) | Boehringer Ingelheim | 2022-09-30 |
| Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan (NCT05402020) | Boehringer Ingelheim | 2022-09-30 |
| A Study in Healthy Men to Test How Different Doses of BI 1584862 Are Tolerated and How BI 1584862 is Taken up in the Body With or Without Food (NCT05520827) | Boehringer Ingelheim | 2022-09-29 |
| A Study in Healthy Men to Test How Different Doses of BI 3032950 Are Tolerated (NCT05518708) | Boehringer Ingelheim | 2022-09-27 |
| A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery (NCT05446129) | Boehringer Ingelheim | 2022-09-27 |
| A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the Body (NCT05515588) | Boehringer Ingelheim | 2022-09-19 |
| A Study in Healthy Men to Test How BI 685509 is Processed in the Body (NCT05515328) | Boehringer Ingelheim | 2022-09-08 |
| A Study in Healthy People to Compare 2 Different Formulations of BI 1015550 Taken With or Without Food (NCT05428436) | Boehringer Ingelheim | 2022-08-15 |
| A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor (NCT05372367) | Boehringer Ingelheim | 2022-08-11 |
| Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease (NCT05465317) | Boehringer Ingelheim | 2022-08-08 |
| Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug (NCT05362487) | Boehringer Ingelheim | 2022-08-05 |
| Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure (NCT05236673) | Boehringer Ingelheim | 2022-07-28 |
| A Study to Test How Healthy Women Tolerate Different Doses of BI 1819479 (NCT05440799) | Boehringer Ingelheim | 2022-07-20 |
| Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients (NCT05401149) | Boehringer Ingelheim | 2022-07-18 |
| A Study in Healthy Men to Test How BI 456906 is Processed in the Body (NCT05421338) | Boehringer Ingelheim | 2022-07-04 |
| A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) (NCT05282121) | Boehringer Ingelheim | 2022-06-28 |
| A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood (NCT05380947) | Boehringer Ingelheim | 2022-06-23 |
| A Study in Healthy Men to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body With or Without Food (NCT05337592) | Boehringer Ingelheim | 2022-06-14 |
| A Study to Test How Well Different Doses of BI 765845 Are Tolerated by Healthy People (NCT06139315) | Boehringer Ingelheim | 2022-06-02 |
| Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice (NCT03205137) | Boehringer Ingelheim | 2022-06-01 |
| A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated (NCT05327946) | Boehringer Ingelheim | 2022-05-17 |
| A Study Based on Japanese Medical Records That Looks at Bleeding Events in People With Atrial Fibrillation and Coronary Artery Disease Who Start Taking Either Dabigatran, Rivaroxaban, or Warfarin (NCT05051904) | Boehringer Ingelheim | 2022-05-17 |
| A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis (NCT05213624) | Boehringer Ingelheim | 2022-05-03 |
| A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active Psoriatic Arthritis (NCT04680676) | Boehringer Ingelheim | 2022-05-02 |
| A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis (NCT05238675) | Boehringer Ingelheim | 2022-04-28 |
| A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906 (NCT05296733) | Boehringer Ingelheim | 2022-04-27 |
| A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) (NCT05161481) | Boehringer Ingelheim | 2022-04-27 |
| Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF) (NCT05262764) | Boehringer Ingelheim | 2022-04-15 |
| 1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients (NCT05395338) | Boehringer Ingelheim | 2022-04-12 |
| A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer (NCT05249426) | Boehringer Ingelheim | 2022-04-12 |
| A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON) (NCT05285982) | Boehringer Ingelheim | 2022-04-06 |
| A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) (NCT05155332) | Boehringer Ingelheim | 2022-03-28 |
| A Study in Healthy Men to Find the Best Formulation for Once Daily Intake of Nintedanib (NCT05262751) | Boehringer Ingelheim | 2022-03-28 |
| Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus (NCT05130463) | Boehringer Ingelheim | 2022-03-22 |
| A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood (NCT05258110) | Boehringer Ingelheim | 2022-03-18 |
| A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab (NCT05068102) | Boehringer Ingelheim | 2022-03-03 |
| A Study in Healthy People to Test How 2 Different Formulations of BI 695501 Are Taken up by the Body When Given as an Injection (NCT05203289) | Boehringer Ingelheim | 2022-02-18 |
| An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options (NCT05200247) | Boehringer Ingelheim | 2022-02-17 |
| A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated (NCT05183360) | Boehringer Ingelheim | 2022-02-07 |
| A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are Tolerated (NCT05183347) | Boehringer Ingelheim | 2022-02-04 |
| A Study to Test How Well Healthy Men Tolerate BI 765250 When Given as an Infusion Into the Vein or as an Injection Under the Skin (NCT05151653) | Boehringer Ingelheim | 2022-01-26 |
| A Study in Healthy People to Compare 2 Different Formulations of BI 1358894 Tablets Taken With or Without Food (NCT05155306) | Boehringer Ingelheim | 2022-01-14 |
| A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease (NCT05182840) | Boehringer Ingelheim | 2022-01-11 |
| To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin (NCT05162014) | Boehringer Ingelheim | 2021-12-20 |
| A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD) (NCT05169424) | Boehringer Ingelheim | 2021-12-17 |
| A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder (NCT05103657) | Boehringer Ingelheim | 2021-12-07 |
| A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease (NCT04978493) | Boehringer Ingelheim | 2021-12-02 |
| A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis (NCT05065190) | Boehringer Ingelheim | 2021-11-25 |
| A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers (NCT05087992) | Boehringer Ingelheim | 2021-11-24 |
| Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas (NCT05102071) | Boehringer Ingelheim | 2021-11-01 |
| A Study in Healthy Men to Test How BI 765080 is Taken up in the Body When Given as an Injection Under the Skin Compared With an Infusion Into the Vein (NCT05075772) | Boehringer Ingelheim | 2021-10-25 |
| A Study in Healthy Men to Test How Fluconazole Influences the Amount of BI 425809 in the Blood (NCT05076409) | Boehringer Ingelheim | 2021-10-19 |
| A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer (NCT04958239) | Boehringer Ingelheim | 2021-10-18 |
| A Study to Test How Well Men Tolerate Different Doses of BI 3006337 (NCT05076422) | Boehringer Ingelheim | 2021-10-18 |
| A Study to Examine Past Estimated Glomerular Filtration Rate (eGFR) Slope as a Risk Marker for Rapid Kidney Function Decline in People With Chronic Kidney Disease (NCT04881448) | Boehringer Ingelheim | 2021-09-16 |
| A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation (NCT04973163) | Boehringer Ingelheim | 2021-09-09 |
| Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1) (NCT04846868) | Boehringer Ingelheim | 2021-09-08 |
| Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database (NCT04903496) | Boehringer Ingelheim | 2021-09-06 |
| A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated (NCT04978506) | Boehringer Ingelheim | 2021-09-03 |
| A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial (NCT04876391) | Boehringer Ingelheim | 2021-08-24 |
| Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2) (NCT04846881) | Boehringer Ingelheim | 2021-08-24 |
| Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients (NCT05022784) | Boehringer Ingelheim | 2021-08-23 |
| CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia (NCT04860830) | Boehringer Ingelheim | 2021-08-09 |
| A Study in Healthy Japanese Men to Test How Different Doses of BI 1569912 Are Taken up by the Body and How Well They Are Tolerated (NCT04958252) | Boehringer Ingelheim | 2021-08-05 |
| A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment (NCT04919499) | Boehringer Ingelheim | 2021-07-30 |
| A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together (NCT05083949) | Boehringer Ingelheim | 2021-07-23 |
| A Study in Healthy Men to Test How BI 474121 is Tolerated (NCT04964453) | Boehringer Ingelheim | 2021-07-21 |
| A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication (NCT04937829) | Boehringer Ingelheim | 2021-07-20 |